Know Cancer

forgot password

A Phase II Trial of Neoadjuvant Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma

Phase 2
18 Years
Open (Enrolling)
Urothelial Cancer, Muscle-invasive Urothelial Carcinoma

Thank you

Trial Information

A Phase II Trial of Neoadjuvant Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma

- Participants will be given a study infusion schedule for each treatment cycle. Each
treatment cycle lasts three weeks. The infusion of methotrexate will take place on the
first day of each cycle. Infusions of vinblastine, doxorubicin and cisplatin will take
place on the second day and an injection of pegfilgrastim will be given on the third

- During all treatment cycles participants will have a physical exam and will be asked
questions about their general health and any problems they might be having and any
medications they may be taking.

- Following completion of study treatment, but before surgery, participants will have an
assessment of their tumor by CT scan of the chest and and MRI of the abdomen and

- Following the participants surgery, we would like to keep track of their medical
condition indefinitely, or until this study is officially completed. We would like to
do this by calling the participants on the telephone once a year to see how they are

Inclusion Criteria:

- Histologic proof of urothelial cancer. Patients with all histologic subtypes are
eligible as long as transitional cell carcinoma is predominant, with the exception of
more than a few clusters of small cell carcinoma, which is treated with different
chemotherapy and thus are ineligible

- Patients with primary tumors arising in the bladder or urethra are eligible if they
have clinical T2-T4a disease

- Patients with primary tumors arising in the ureter or renal pelvis are eligible if
they have either grade 3 tumors, or radiographic abnormality large enough to be
recognized as an abnormal mass by CT/imaging

- Evaluation by a urologist and be deemed to be acceptable surgical candidates within 3
months of registration

- Adequate physiologic reserves as outlined in the protocol

- Clinical or pathologic N1 lymph node involvement (involvement of a single lymph node
< 2cm in greatest dimension) are eligible. Patients with N2-3 or M1 disease are

- Determination of LV function with an EF > 50%

- Women of child-bearing potential must have a negative pregnancy test

- Patients of child-bearing or father-bearing potential must agree to use an acceptable
form of birth control while on the study

- Patients with prior malignancy are eligible provided that the expected outcome from
the prior cancer is such that this will not interfere in the delivery of this
therapy, or the assessment of response in the cystectomy specimen

- 18 years of age or older

Exclusion Criteria:

- Current, recent (within 3 weeks), or planned participation with other experimental
anti-cancer medications as part of clinical trials

- Prior treatment with doxorubicin

- Prior systemic cytoreductive chemotherapy for bladder cancer

- Blood pressure of > 160/100 mmHg. Patients whose blood pressure can be controlled
with oral medication are eligible

- NYHA Grade II or greater congestive heart failure

- History of myocardial infarction or unstable angina within 6 months prior to study

- History of stroke or transient ischemic attack within 6 months prior to study

- Clinically significant peripheral vascular disease

- Evidence of bleeding diathesis or coagulopathy

- Known history of central nervous system or brain metastases

- Major surgical procedure, significant traumatic injury within 21 days prior to Day 1,
or anticipation of need for major surgical procedure during the course of the study

- Lactating women

- Patients who are not candidates for surgery, or unwilling to undergo surgery

- Patients with significant fluid collection

- Known hypersensitivity to any component of cisplatin, methotrexate, vinblastine,
doxorubicin or pegfilgrastim

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To estimate the pathologic response of this patient population treated with neoadjuvant chemotherapy and pegfilgrastim followed by radical surgery with curative intent.

Outcome Time Frame:

3 years

Safety Issue:


Principal Investigator

Toni Choueiri, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Dana-Farber Cancer Institute


United States: Institutional Review Board

Study ID:




Start Date:

December 2008

Completion Date:

December 2013

Related Keywords:

  • Urothelial Cancer
  • Muscle-invasive Urothelial Carcinoma
  • pegfilgrastim
  • MVAC
  • Carcinoma
  • Carcinoma, Transitional Cell



Beth Israel Deaconess Medical Center Boston, Massachusetts  02215
University of Pittsburgh Cancer Institute Pittsburgh, Pennsylvania  15213
Dana-Farber Cancer Institute Boston, Massachusetts  02115
Lahey Clinic Burlington, Massachusetts  01805